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A B S T R A C T
A phytochemical investigation of the root extracts of Salvia tebesana Bunge led to the isolation of two new
diterpenoids, tebesinone A (1) and tebesinone B (2), along with two known compounds, aegyptinone A (3) and
aegyptinone B (4). The structures were established by spectroscopic analysis including 1D and 2D NMR and
HRESIMS. The cytotoxic activities of the crude extracts and isolated compounds were evaluated against MCF-7,
B16F10, PC-3 and C26 human cancer cell lines, in which compounds 2 and 3 showed signiﬁcant cytotoxic
activities (IC50 2.1–10.3 μM).
1. Introduction
Salvia is one of the largest genera of the Lamiaceae family with over
900 species in the world which about 58 species are distributed in Iran,
17 of them are endemic [1]. The genus Salvia distributed extensively
throughout tropical and temperate regions [2]. Some members of the
genus Salvia are used in Iranian folk medicine. For example, S. sclarea as
tonic, S. macrosiphon as antimicrobial, S. hydrangea and S. mirzayanii
have antispasmodic and anti-inﬂammatory eﬀects, respectively [3,4].
Phytochemically, a variety of compounds have been reported from
the genus of Salvia including ﬂavonoids, caﬀeoyl derivatives, sesqui-
terpenoids, diterpenoids, triterpenes, sesterterpenes, steroids and es-
sential oils [3,5,6]. Diterpenoids extracted from Salvia species are
mainly based on abietane and clerodane skeletons that produced
mainly in the roots of plants [7,8]. The plant of this genus showed
diﬀerent biological activities such as antioxidant [9], antifungal [10],
cytotoxic [11], diuretic [12], antibacterial [13], hemostatic, sedative
and anticancer [14]. The anticancer and cytotoxic constituents of genus
Salvia are related to terpenoids, while abietane diterpenoids are re-
sponsible for the antibacterial and antifungal activities. Phenolic com-
pounds, especially caﬀeic acid derivatives were found as potent anti-
viral agents in Salvia species [3].
Salvia tebesana Bunge is one of the Iranian endemic species that
distributed around Tabas, Iran and locally named “Maryamgoli Tabasi”.
Recently, the essential oil of S. tebesana has been analyzed by GC–MS
and α-pinene, 7-epi-α-eudesmol, caryophyllene oxide and (E)-
caryophyllene have been detected as major constituents [15]. To the
best of our knowledge in this study for the ﬁrst time, two new di-
terpenoids, tebesinones A (1) and B (2) along with two known abietane
diterpenoids including aegyotinone A (3) [16] and B (4) [17] were
isolated from the roots of S. tebesana.
2. Experimental
2.1. General experimental procedures
UV spectra were recorded using a Shimadzu UV1650 spectrometer
and infrared (IR) spectra were run on Spectrum Two FTIR spectrometer
(Perkin Elmer, USA). NMR spectra were obtained using Bruker
AVANCE Ш-300 spectrometer (Bruker, Germany). Optical rotations
were recorded on a Polax-2L ATAGO, digital polarimeter at 25 °C
(ATAGO Co. Ltd., Tokyo, Japan). High-resolution MS data were re-
corded on a Thermo Q Exactive plus Orbitrap mass spectrometer
equipped with HESI source. The resolution was over 40,000. The data
were acquired and processed with Thermo Xcalibur 4.0 software. Silica
gel 230–400 mesh (Merck, Germany) was used for column chromato-
graphy (CC). Semipreparative HPLC was performed on a KNAUER li-
quid chromatograph system with a quaternary pump (Smartline Pump
1000) and semi-prep C18 column (onyx monolithic; 100×10mm).
Diode array detector (Smartline DAD 2800) and EZ Chrom Elite soft-
ware were used for detection and processing of data respectively.
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2.2. Plant material
The roots of Salvia tebesana Bunge were collected in April 2017 from
its natural habitat near Tabas, South Khorasan Province. The plant was
identiﬁed by Mr. M.R. Joharchi, from the Ferdowsi University of
Mashhad Herbarium (FUMH). A specimen of this plant (No. 24864) was
deposited in the herbarium of School of Pharmacy, Mashhad University
of Medical Sciences.
2.3. Extraction and isolation
The dried roots (1500 g) were extracted three times with MeOH
(each 24 h) at room temperature. The whole extract was ﬁltered and the
solvent was evaporated under vacuum aﬀording crude extract (30 g).
Methanol extract was further fractionated by solvent-solvent partition
to give four diﬀerent fractions [petroleum ether (40–60 °C), di-
chloromethane (CH2Cl2), butanol (n-BuOH) and water (H2O)] ac-
cording to Otsuka method [18]. The isolated fractions were con-
centrated in vacuo to yield residues of 4.2, 7.0, 4.5 and 10 g
respectively. Based on the cytotoxic activity test the CH2Cl2 fraction
(7 g) with high potency was subjected to silica-gel column chromato-
graphy (55×5 cm) eluted with petroleum ether–ethyl acetate (100:0
to 0:100) to give eighteen fractions (Fr.1–18) with the aid of TLC
analysis. The fractions were separated via normal phase open columns
and further puriﬁed by semipreparative HPLC-C18 column chromato-
graphy using MeOH-H2O (20:80). Compound 1 (3 mg, tR 8.46min) was
obtained from Fr.6 using a petroleum ether–EtOAc (80:20) as a yellow
powder; Compound 2 (8 mg, tR 9.86min) was obtained from Fr.15
using a petroleum ether–EtOAc (60:40) as orange prism; Compound 3
(50mg, tR 9.23min) was isolated from Fr.11 using a petroleum ether
–EtOAc (70:30) as dark-orange prism and compound 4 (3 mg, tR
8.78min) obtained from Fr.17 using a petroleum ether –EtOAc (50,50)
as dark red plates.
2.3.1. Tebesinone A (1)
Yellow powder; [α]D25+ 20 (c 0.1, MeOH); UV (MeOH) λmax (log ε)
366 (1.15), 368 (1.15), 400 (1.00), 423 (0.54) nm; IR νmax (MeOH)
2957, 2929, 1729, 1645, 1580, 1268, 1078, 1040 and 803 cm−1; 1H
NMR, 13C NMR and HMBC data see Table 1. HR-ESI-MS positive m/z
311.1640 [M+H]+ (calcd for C20H23O3, 311.1647).
2.3.2. Tebesinone B (2)
Orange prism; [α]D25+ 5 (c 0.1, MeOH); UV (MeOH) λmax (log ε)
364 (4.75), 400 (3.38), 423 (3.72), 431(3.78) nm; IR νmax (MeOH)
3437, 2962, 2929, 1655, 1580, 1259, 1027 and 798 cm−1; 1H NMR, 13C
Table 1
1H and 13C NMR spectroscopic data of compounds 1 and 2 (300MHz in CDCl3,
δ in ppm, J in Hz).
Position 1 2
δH δC HMBC δH δC HMBC
1 2.67 t
(6.4)
28.7 C-2,C-3,C-
5,C-6
2.66 t
(6.4)
28.1 C-2,C-3,C-5,C-
6,C-10
2 1.79m 19.2 C-4,C-6 1.82m 19.1 C-4,C-5
3 1.58m 37.9 C-1,C-2,C-
6,C-18
1.62m 37.8 C-1,C-2,C-18
4 35.0 34.8
5 142.0 139.0
6 152.1 145.2
7 7.96 s 123.4 C-4,C-5,C-
9,C-14
7.12 s 127.4 C-4,C-8,C-9,C-
14
8 132.4 139.9
9 126.4 126.4
10 141.2 153.7
11 180.5 182.5
12 161.1 7.18 s 143.5 C-9,C-11,C-13,
C-15
13 125.7 133.3
14 182.6 182.2
15
16a
16b
3.58m
4.24 dd
(8.6, 6.5)
4.74 t
(9.4)
35.6
80.0
C-13
C-12,C-13,
C-15,C-17
3.07m
3.67m
3.70m
35.4
66.4
C-8,C-16,C-17
C-13,C-15,C-17
17
18
1.32 d
(6.9)
1.27 s
18.9
31.2
C-13,C-
15,C-16
C-1,C-3,C-6
1.22 d
(7.1)
1.29 s
15.5
31.2
C-13,C-15,C-16
C-3,C-6
19 1.27 s 31.2 1.29 s 31.2
20 2.57 s 16.7 C-9,C-10,C-
11
2.54 s 16.7 C-5,C-6,C-9
Fig. 1. Chemical structures of compounds 1–4.
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NMR and HMBC data see Table 1. HR-ESI-MS positive m/z 313.1796
[M+H]+ (calcd for C20H25O3, 313.1804), 335.1616 [M+Na]+
(calcd for C20H24O3Na, 335.1623), 295.1692 [M+H−H2O]+ (calcd
for C20H23O2, 295.1698).
2.4. Cytotoxic activity of compounds
2.4.1. Cancer cell lines
Human breast adenocarcinoma (MCF-7), melanoma (B16F10),
prostate (PC-3) and colon (C26) cancer cells were obtained from
Biotechnology Research Center (Mashhad, Iran), Pasteur Institute
(Tehran, Iran). Cell lines maintained in 75 cm2 culture ﬂasks in RPMI
1640 medium supplemented with 10% fetal bovine serum and anti-
biotics (100mg/mL penicillin/streptomycin) at 37 °C in an atmosphere
of 95% O2 and 5% CO2.
2.4.2. Cell viability assay
The cytotoxic eﬀect of compounds against MCF-7, B16F10, PC-3 and
C26 was determined using a non-ﬂuorescent substrate, AlamarBlue®.
Cells (1.5× 104 cells/well) were plated in 96-well plates in 100 μL of
medium, in which the test samples were added at various concentra-
tions (2.5 to 50 μM). Three wells for each concentration were seeded
and triplicate plates were used. Then, the cells were incubated in CO2
incubator. After 48 h in culture at 37 °C in 5% CO2, 20 μL of
AlamarBlue® reagent was added to the attached cells. After 4 h, the cell
viability was determined by measuring the absorbance at 600 nm using
an ELISA microplate reader. Doxorubicin was used as a positive control.
3. Results and discussion
The dichloromethane extract of the roots of Salvia tebesana was
subjected to silica gel column chromatography eluting with petroleum
ether–EtOAc and then further puriﬁed by semipreparative HPLC to af-
ford two new diterpenoids (tebesinone A and B, 1, 2) and two known
analogues aegyptinone A (3) and aegyptinone B (4).
Compound 1 was isolated as a yellow powder. A molecular formula
of C20H22O3 was determined by HR-ESI-MS data (m/z 311.1640
[M+H]+ (calcd for C20H23O3, 311.1647), accounting for ten degrees
of unsaturation. Its UV maxima (366, 368, 400 and 423 nm) and IR
bands (1729, 1645, 1580 cm−1) suggested that 1 contained aromatic
ring and carbonyl group. The 13C NMR and 1H NMR spectroscopic data
exhibited 20 carbon signals including one pentasubstituted aromatic
ring (δC/δH 123.4/7.96, 141.2, 142.0, 152.1, 126.4, 132.4), two car-
bonyl group (δC 182.6, 180.5), one dihydromethylfuran ring (δC/δH
O
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Fig. 2. Key HMBC correlations of compounds 1 and 2.
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Fig. 3. Proposed biosynthetic pathway of tebesinone A (2).
Table 2
IC50 values (μg/mL) for diﬀerent extracts of S. tebesana.
Compound IC50 (μg/mL)
MCF-7 B16F10 PC-3 C26
Petroleum ether 17.48 ± 0.72 12.18 ± 0.6 9.265 ± 0.67 18.17 ± 1.09
Dichloromethane 33.98 ± 2.22 18.88 ± 1.73 15.68 ± 1.56 45.28 ± 0.97
Methanol 46.09 ± 1.68 24.15 ± 2.06 29.21 ± 3.28 >50
Butanol
Doxorubicina
> 50
2.08 ± 0.25
>50
0.01 ± 0.21
>50
1.51 ± 0.34
>50
0.85 ± 0.14
a Positive control substance.
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35.6/3.58, 80.0/4.24, 4.74, 161.1, 125.7), three additional methylenes
(δC/δH 28.7/2.67, 19.2/1.79, 37.9/1.58,), four methyls (δC/δH
2× 31.2/1.27, 16.7/2.57, 18.9/1.32). The dihydromethylfuran ring
was consistent with the following 1H NMR data: a methyl doublet at δ
1.32 (C-17, 3H) coupled to a methine multiplet at δ 3.58 (C-15, 1H),
which was coupled to a and b methylene protons at δ 4.24 (C-16a, 1H)
and δ 4.74 (C-16b, 1H) and its location was conﬁrmed by the HMBC
correlations in position C-16 with regard to the long-range correlation
between H-16 to C-15, C-17, C-13 and C-12. Additionally, in the HMBC
spectrum, H-7 (s 7.96) showed correlations with C-4 (35.0), C-5
(142.0), C-9 (126.4) and C-14 (182.6), while H-20 (s 2.57) showed
cross-peaks with C-10 (141.2), C-9 (126.4) and C-11 (180.5). In parti-
cular, the 13C NMR spectrum conﬁrmed the presence of a paraquinone
system by the observation of two quaternary carbon signals at δ 182.6
and 180.5 and the existence of an ether linkage involving sp2 and sp3
carbons assigned as C-12 (δ 161.1) and C-16 (δ 80.1), respectively.
Also, some impurities such as signals in 1H NMR (2.1 ppm) and HMBC
(210 ppm) are related to the impurity of Acetone-d6 and the chemical
shift in 7.2 ppm belongs to CDCl3. The structure of 1 was similar to
aegyptinone A which isolated by Sabri from S. aegyptiaca by comparison
of their NMR spectroscopic [16]. The presence of a paraquinone system
instead of orthoquinone in aegyptinone A, was the main diﬀerence in
the spectrum of tebesinone A. Finally, the structure of 1 was elucidated
and named tebesinone A (Fig. 1).
Compound 2 was isolated as an orange prism. The HR-ESI-MS in-
dicated the molecular formula C20H24O3 (m/z 313.1796 [M+H]+
(calcd for C20H25O3, 313.1804)) which showed night degrees of un-
saturation. The UV absorptions of compound 2 at 364, 400, 423 and
431 nm indicted a highly conjugated system. The IR absorptions at
3437, 1655, 1580 cm−1 implied the existence of OH, carbonyl groups.
The 13C NMR indicated 20 carbon signals which in combination with 1H
NMR and HSQC experiments showed the presence of one pentasub-
stituted aromatic ring (δC/δH 127.4/7.12, 139.0, 145.2, 139.9, 126.4,
153.7), two carbonyl group (δC 182.5, 182.2), two methines (δC/δH
143.5/7.18, 35.4/3.07), four methylenes (δC/δH 28.1/2.66, 19.1/1.82,
37.8/1.62, 66.4/3.67, 3.70), four methyls (δC/δH 31.2/1.29, 16.7/2.54,
15.5/1.22). Additionally, the 13C NMR spectrum supported the pre-
sence of a paraquinone system by the observation of two quaternary
carbon signals at δ 182.5 and 182.2. Also, in HMBC spectrum H-7 (s
7.12) showed cross-peaks with C-4 (34.8), C-5 (139.0), C-9 (126.4) and
C-14 (182.2), while H-12 (s 7.18) showed correlations with C-9 (126.4),
C-11 (182.5), C-13 (133.3) and C-15 (35.4). In addition, the chemical
shift in 7.59 ppm belongs to CDCl3 and the impurities observed in 1H
NMR (2.1 ppm) and HMBC (210 ppm) related to impurity of Acetone-
d6. The structure of 2 was similar to those of aegyptinone B isolated by
El-Lakany from S. aegyptiaca by comparison of their NMR spectroscopic
[17]. The main diﬀerence was the presence of methine (δC/δH 143.5/
7.18C-12) in 2 instead of 12-hydroxyl group in aegyptinone B which
was further conﬁrmed by HMBC correlations from H-12 to C-11, C-13,
C-9 and C-15. Finally, the structure of 2 was elucidated and named
tebesinone B (Fig. 1). The key HMBC correlations of compounds 1 and 2
are shown in Fig. 2.
Sabri et al. reported the biogenetic pathway of aegyptinones A and B
which could plausibly be traced back to 6,7-didehydroroyleanone [16].
From a biogenetic point of view, proton exchange would lead to the
formation of rearranged abietane skeleton. These ﬁndings conﬁrm si-
milar evidence of tebesinone B occurrence in Salvia tebesana (Fig. 3).
The various extracts and compounds of S. tebesana were examined
for cytotoxicity on MCF-7, B16F10, PC-3 and C26 cell lines (Table 2).
All of the extracts except BuOH, showed activity against all tested cell
lines (IC50 9.2–46.09 μg/mL). Aegyptinone A (3) and tebesinone B (2)
showed the highest cytotoxic activity against MCF-7, B16F10, PC-3 and
C26 cell lines (IC50 2.1–10.3 μM), but tebesinone A (1) did not show
cytotoxic activity (> 50 μM). Aegiptinone B (4) exhibited high activity
against PC-3 cell line (IC50 5.79 μM) (Table 3). The results suggested
that aegyptinone A (3) and tebesinone B (2) may have potent anti-
growth activity on cancer cell line.
4. Conclusion
In this study, four diterpenoids including two new namely tebesi-
nones A (1) and B (2) and two known named aegyptinones A and B (3,
4) were isolated from the roots of Salvia tebesana, an endemic plant of
Iran. The cytotoxic activities of the isolated compounds were evaluated
against four human cancer cell lines, in which aegyptinone A and te-
besinone B showed signiﬁcant cytotoxic activities against PC3 cells with
IC50 values of 2.11 and 5.47 μM. Further studies should be carried out
for determination of the mechanism of action of the cytotoxic com-
pounds.
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